These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 20880269

  • 1. The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment.
    Imamura K, Okayasu N, Nagatsu T.
    Acta Neurol Scand; 2011 Jul; 124(1):28-39. PubMed ID: 20880269
    [Abstract] [Full Text] [Related]

  • 2. Cerebral blood flow and freezing of gait in Parkinson's disease.
    Imamura K, Okayasu N, Nagatsu T.
    Acta Neurol Scand; 2012 Sep; 126(3):210-8. PubMed ID: 22324564
    [Abstract] [Full Text] [Related]

  • 3. Brain perfusion alterations in depressed patients with Parkinson's disease.
    Kim YD, Jeong HS, Song IU, Chung YA, Namgung E, Kim YD.
    Ann Nucl Med; 2016 Dec; 30(10):731-737. PubMed ID: 27566684
    [Abstract] [Full Text] [Related]

  • 4. Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study.
    Im JJ, Jeong H, Chung YA, Park JS, Heo Y, Oh JK, Song IU.
    J Neuroimaging; 2019 Nov; 29(6):707-711. PubMed ID: 31463990
    [Abstract] [Full Text] [Related]

  • 5. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 6. Brain networks underlying the clinical effects of long-term subthalamic stimulation for Parkinson's disease: a 4-year follow-up study with rCBF SPECT.
    Sestini S, Ramat S, Formiconi AR, Ammannati F, Sorbi S, Pupi A.
    J Nucl Med; 2005 Sep; 46(9):1444-54. PubMed ID: 16157526
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Changes in regional cerebral blood flow caused by deep-brain stimulation of the subthalamic nucleus in Parkinson's disease.
    Sestini S, Scotto di Luzio A, Ammannati F, De Cristofaro MT, Passeri A, Martini S, Pupi A.
    J Nucl Med; 2002 Jun; 43(6):725-32. PubMed ID: 12050315
    [Abstract] [Full Text] [Related]

  • 10. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E, Cilia R, Canesi M, Tesei S, Mariani CB, Zecchinelli AL, Pezzoli G.
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cognitive functions in Parkinson's disease: relation to disease severity and hallucination.
    Wakamori T, Agari T, Yasuhara T, Kameda M, Kondo A, Shinko A, Sasada S, Sasaki T, Furuta T, Date I.
    Parkinsonism Relat Disord; 2014 Apr; 20(4):415-20. PubMed ID: 24467818
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Changes in regional cerebral blood flow following antidepressant treatment in late-life depression.
    Ishizaki J, Yamamoto H, Takahashi T, Takeda M, Yano M, Mimura M.
    Int J Geriatr Psychiatry; 2008 Aug; 23(8):805-11. PubMed ID: 18214999
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A, Johnson ES, Mallard N, Corn TH, Johnston A, Boyce M, Warrington S, MacMahon DG.
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.